Brought to you by 
Arkray KDK gets Asian rights to Biosite cardiac test
30 Jun 2020
Executive Summary
Arkray KDK (formerly Kyoto Dai-ichi Kagaku) licensed exclusive development and marketing rights to Biosite's (point-of-care tests) Triage Cardiac test in Japan, certain Asian countries, the Middle East, and Pacific Islands.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arkray KDK gets Asian rights to Biosite cardiac test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice